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Abstract
 .We studied the ATP-dependent uptake of dinitrophenyl-glutathione GS-DNP into plasma membrane vesicles derived
from parental GLC4 cells and from multidrug resistant GLC4rADR cells. The latter have a high expression of the
 .multidrug resistance protein MRP . Uptake of GS-DNP into membrane vesicles from GLC4rADR cells was highly
stimulated by the addition of ATP, compared to the uptake into membrane vesicles from GLC4 cells. This ATP-dependent
uptake into membrane vesicles from GLC4rADR cells was saturable with a K of 1.2"0.2 mM and a V of 560"80m max
pmolrmg prot.rmin. ATP stimulated GS-DNP uptake with a K of 187"4 mM. This uptake was specifically inhibited bym
a polyclonal serum raised against a fusion protein containing a segment of MRP. The ATP-dependent uptake of GS-DNP
 .  .was not only inhibited by organic anions, such as oxidized glutathione GSSG , methotrexate MTX and some bile acids,
 .but also by non-anionic natural product drugs, such as anthracyclines, vinca alkaloids and etoposide VP-16 . Uptake of
GSSG and MTX into membrane vesicles from GLC4rADR cells could be stimulated by ATP. The ATP-dependent uptake
of GSSG had a K of 43"3 mM and a V of 900"200 nmolrmg proteinrmin. The ATP-dependent uptake ofm max
 .GS-DNP seemed to be non-competitively inhibited by the anthracycline daunorubicin DNR , whereas the ATP-dependent
GSSG uptake seemed to be competitively inhibited by DNR. A substrate binding site on MRP is proposed that comprises a
pocket in which both DNR and GS-DNP or GSSG bind in random order to different, only partly overlapping sites. In this
pocket binding of a second compound is influenced by the compound which was bound first.
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1. Introduction
Cancer cells selected for resistance against natural
product drugs, such as doxorubicin, are often cross-
resistant to a range of structurally and functionally
unrelated drugs. This type of drug resistance is called
 .multidrug resistance MDR . The classical form of
MDR is caused by the enhanced expression of the
 .MDR1 gene, which encodes the P-glycoprotein Pgp .
Pgp is an ATP-dependent drug export pump located
w xin the plasma membrane of various cell types 1 .
Recently, a second ATP-dependent transporter of
anti-tumor drugs has been identified in mammalian
 . w xcells, the multidrug resistance protein MRP 2 .
Transfection studies showed that MRP could confer
resistance to a wide spectrum of natural product
w xdrugs 3,4 . MRP overexpressing cells are resistant to
anthracyclines, to vinca alkaloids and especially to
w xetoposide 4–8 . Expression of MRP did not confer
w xresistance to cisplatin 5,6 .
Isolated plasma membrane vesicles of MRP-trans-
fected cells exhibited an ATP-dependent transport of
 .glutathione GS -conjugates, such as leukotriene-C4
 .and dinitrophenyl-glutathione GS-DNP . Vesicles
from untransfected cells exhibited only little such
w xtransport 9,10 . In addition, isolated plasma mem-
brane vesicles from drug-resistant cell lines that over-
 .express MRP GLC4rADR and HL60rADR pos-
sessed an ATP-dependent transport system for GS-
conjugates. This transport activity was almost absent
in the parental human small-cell lung cancer cell line,
w xGLC4, and the leukemic cell line HL60 10,11 .
The studies with isolated plasma membranes sug-
gested that MRP functions as a transporter of nega-
tively charged GS-conjugates. In experiments with
intact cells, expression of MRP also conferred resis-
tance to neutral and positively charged amphiphilic
drugs. It has been suggested that these drugs are
metabolized to anionic compounds that are trans-
ported by MRP. Reduction of the cellular glutathione
 .GSH content by inhibiting its synthesis with buthio-
nine sulfoxime, decreased drug resistance to daunoru-
 . wbicin DNR in MRP overexpressing cell lines 12–
x15 . This suggested that the conjugation with glu-
tathione might be the relevant metabolism or that
 .glutathione is involved in a transient complex for-
mation. No such effect was seen in Pgp overexpress-
w xing cell lines 13–15 . Pgp transports unconjugated
w xDNR 16 . However, such metabolites of, for in-
stance, DNR have not been found in MRP drug-re-
sistant cell lines and it has not yet been excluded that
w xDNR itself is transported by MRP 17 .
In order to gain more insight into the substrate
specificity of MRP, we isolated plasma membrane
vesicles of GLC4rADR cells and studied the ATP-
dependent uptake of GS-DNP into these vesicles.
This transport could be inhibited by several anionic
and cationic drugs.
2. Materials and methods
2.1. Chemicals
w3 x  .H GSH 1.6 TBqrmmol was purchased from
 .New England Nuclear Dreieich, Germany . Dithio-
w3 xthreitol was removed from this solution of H GSH
w x w3 xaccording to Butler et al. 18 . H GS-DNP was
synthesized by conjugation of 1-chloro-2,4-dinitro-
 . w3 xbenzene CDNB to H GSH. To a solution of 20
w3 xmM H GSH and 1 mM CDNB, 1% NH OH was4
added. When the reaction was complete, acetic acid
  . . w3 xwas added 5% wrv final concentration . H GS-
w3 xDNP and H GSSG were separated on a reverse-
phase C column volume 1 ml, J.T. Baker, Phillips-18
.burg, USA equilibrated with 5% acetic acid. After
 .addition of the reaction mixture 100 ml , the column
w3 xwas washed with 5% acetic acid. H GS-DNP was
 .eluted with 30% vrv ethanol in 5% acetic acid.
w xUnlabelled GS-DNP was purified by TLC 19 .
w3 x  .H Methotrexate 866 GBqrmmol was from
 .Moravek Biochemicals Brea, California, USA and
w3 x  .H DNR hydrochloride 163 GBqrmmol from
Dupont de Nemours ’s-Hertogenbosch, the Nether-
.lands .
DNR hydrochloride was obtained from Specia
 .Paris, France , doxorubicin hydrochloride from Lab-
 .  Xoratoire Roger Bellon France , and idarubicin 4 -de-
.methoxy-daunorubicin was kindly provided by Dr.
J.W. Scheeren Catholic University of Nijmegen, the
.Netherlands . Methotrexate was obtained from Phar-
 .machemie BV Haarlem, the Netherlands , taxol from
Bristol-Myers Squibb BV Woerden, the Nether-
. lands , and VP-16 from TEVA Pharma Mijdrecht,
.the Netherlands . ATP was obtained from Boehringer
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 .Mannheim Almere, the Netherlands . All other or-
 .ganic compounds were from Sigma St. Louis, USA .
Cell culture media and supplements were obtained
 .from Flow Laboratories Irvine, UK . Fetal calf serum
 .  .FCS was from Gibco Paisley, UK .
2.2. Polyclonal antibodies
Polyclonal antibodies were obtained by immuniz-
ing mice, a rat and a guinea pig against bacterial
fusion proteins containing segments of MRP. The
 .MRP segments used were amino acids 192-360 FP-I ,
 .  .986-1204 FP-V and 1294-1430r1497-1531 FP-III .
The construction of the fusion proteins, the immu-
nization protocol and the isolation of rat and mice
anti-MRP monoclonal antibodies from these animals
w xhas been described by Flens et al. 20,21 .
2.3. Cells
The GLC4 and GLC4rADR human small cell
w xlung cancer cell lines 22 were grown in RPMI
medium supplemented with 7% heat-inactivated FCS
at 378C in a humidified atmosphere of 5–6% CO .2
The GLC4rADR cell line was cultured in the pres-
ence of 1 mM of DOX until one week before plasma
membrane isolation.
2.4. Plasma membrane ˝esicles
Plasma membrane vesicles derived from GLC4
and GLC4rADR cells were isolated following a
w xmethod adapted from Garrigos et al. 23 . Cells were
 .harvested by centrifugation 275=g, 5 min and
washed once in phosphate-buffered saline. After in-
cubating the cells in 100 mM KCl, 5 mM MgCl , 12
 .mM PMSF and 50 mM HepesrKOH pH 7.4 for 1 h
on ice, the cells were ultrasonicated at 20% of the
maximum power of an M.S.E. Soniprep 150 sonica-
 .tor for 3 bursts of 15 s. The homogenate 2.5 mgrml
 .was centrifuged 1500=g, 10 min . The post-nuclear
supernatant was layered on top of a 46% sucrose
 .cushion. After centrifugation 100 000=g, 60 min
the interface was removed and washed in 100 mM
 . KCl and 50 mM HepesrKOH pH 7.4 100 000=g,
.20 min The final pellet was resuspended in 100 mM
 .KCl and 50 mM HepesrKOH pH 7.4 by drawing
the suspension 5 times through a 27-G needle. The
final membrane preparations were stored at y808C at
a protein concentration of ;4 mgrml.
Marker enzyme activities were measured to deter-
q q mine enrichment of Na -K -ATPase plasma mem-
. w x  . w xbrane 24 , of esterase endoplasmic reticulum 25 ,
 . w xof acid phosphatase lysosomes 26 and of gluta-
 . w xmate dehydrogenase mitochondria 27 . Protein was
 .determined by the Bio-Rad Munchen, Germany pro-¨
tein assay.
2.5. Uptake studies
Uptake was measured by rapid filtration as previ-
w x ously described 28 . Plasma membrane vesicles ;
.0.25 mg proteinrml were incubated for the indicated
time at 378C in 100 mM KCl, 50 mM HepesrKOH
 .pH 7.4 , 10 mM MgCl with or without 2 mM ATP2
w3 x and with either H GS-DNP 1.6 kBqrpmol, 32
. w3 x  .Bqrml or H GSSG 3.2 kBqrpmol, 32 Bqrml or
w3 x  .H methotrexate 636 Bqrpmol, 190 Bqrml . Incu-
bation was stopped by adding 2.5 ml of ice-cold 100
 .mM KCl, 50 mM HepesrKOH pH 7.4 to 50 ml of
the uptake medium. When the incubation time ex-
ceeded 5 min 50 ml was removed from a larger
volume, incubated in a closed vial to prevent evapo-
ration. After rapid filtration, filters OE67, Schleicher
.and Schuell, Dassel, Germany were washed twice
 .with the stop buffer 2.5 ml . Both substrate and
inhibitors were mixed with the vesicles at the start of
the incubation. Polyclonal antibodies were preincu-
bated on ice with the plasma membrane vesicles for
at least 1 h, giving a 25 times dilution of the anti-
serum in the final incubation medium. The ATP-de-
pendent uptake was determined by the difference
between the uptake in the presence and that in the
absence of ATP.
2.6. Calculations
The rate equation for the pocket model was de-
rived from the following scheme.
In this scheme the binding site is represented by E.
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Fig. 1. ATP-dependent uptake of GS-DNP into membrane vesi-
cles of parental GLC4 and multidrug resistant GLC4rADR cells
w3 xas function of time. Uptake of 10 nM H GS-DNP into mem-
 . brane vesicles of GLC4 dashed, v, ‘ and GLC4rADR I,
.  .  .B was measured in the presence v, B or the absence ‘, I
of ATP as described in Section 2. Data are from a representative
experiment.
Binding of substrate S and inhibitor I to E occurs in
random order. The relative amount of the different
 .binding site forms E, ES, IE and IES depends on
the concentrations of I and S and on the dissociation
equilibrium constants of S for ES and IES, K ands
. K ra , respectively and of I for IE and IES, K ands i
.K ra , respectively . These constants certify micro-i
scopic reversibility. The binding co-operativity index
a can be written as e-wr kT where w is the ‘‘interac-
tive free energy’’ of S with I at the binding site T is
.temperature in Kelvin and k the Boltzmann constant
ww x  .x  .29 page 168 . If w40 a“0 then binding is
 .competitive, if w)0 a-1 then binding is nega-
 .tively co-operative, if ws0 as1 then binding is
 .non-competitive and if w-0 a)1 then binding is
positively co-operative. From ES and IES, S is trans-
w x w x Xported at rates ES Pk and IES Pk , respectively.v v
This transport rate was supposed to be much smaller
than the dissociation rates of S or I from the binding
site. This might be a valid assumption because for the
related transporter P-glycoprotein it was estimated
that the dissociation rate constant of daunorubicin
3 y1 w xwas 1P10 s 30 and that the catalytic rate con-
 . y1 w xstant k was 2–15 s 31,32 . This catalytic ratev
constant is comparable with the estimated catalytic
w x w xrate constant for MRP 33 . Calling E Pk sVtotal v max
and kX rk s f the rate equation of the transport of Sv v
becomes
S S I
V q famax  /K K Ks s i˝s S I S I
1q q qa
K K K Ks i s i
In Section 3, data are presented as mean"S.E.M.
 .Signifance of differences P-0.05 between values
were calculated with the Student t-test and between
variations of the fits with an F-test.
3. Results
The final plasma membrane fraction had an enrich-
ment of Naq-Kq-ATPase by 5 times, of esterase by
1.4 times, of acid phosphatase by 2.5 times and of
glutamate dehydrogenase by 0.3 times as compared
to whole cells. In the assay, additional effective
enrichment was obtained by only considering the
ATP-dependent part of the uptake rate.
3.1. GS-DNP uptake
Uptake of GS-DNP into membrane vesicles of
GLC4rADR was stimulated by the addition of ATP
Table 1
Kinetic constants of the ATP-dependent GSDNP and GSSG uptake into GLC4rADR membrane vesicles
GS-DNP uptake GSSG uptake
 .  .K 1.2"0.2 ns8 43"3 ns4 mMm
 .  .V 560"80 ns8 900"200 ns4 pmolrmg.proteinrminmax
 .K 187"4 ns4 mMm,ATP
The kinetic parameters were derived from n separate experiments as depicted in Fig. 2. The uptake of GS-DNP was measured in 15 s and
of GSSG in 6 min. Data are presented as mean"S.E.M.
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 .Fig. 1 . ATP did not give such a stimulation of the
GSDNP uptake into vesicles of the parental cell line,
GLC4. The ATP-dependent uptake of GS-DNP into
Fig. 2. ATP and GS-DNP concentration dependence of the
ATP-dependent GS-DNP uptake into membrane vesicles of
w3 xGLC4rADR cells. Uptake of H GS-DNP into membrane vesi-
cles of GLC4rADR in 15 s was measured at different GS-DNP
 .concentrations, ranging from 20 to 5000 nM GS-DNP, with v
 .  .or without ‘ 1 mM of ATP A and at different ATP concen-
trations, ranging from 20 to 1000 mM ATP, at 5 mM GS-DNP
 .  .B . The dashed line upper panel indicates the ATP-dependent
uptake of GSDNP, obtained by subtracting the uptake of GS-DNP
 .in the absence of ATP lower curve from the uptake in the
 .presence of ATP upper curve . Data are from a representative
experiment.
Fig. 3. Interaction of polyclonal antisera with the ATP-dependent
GS-DNP uptake into membrane vesicles from GLC4rADR cells.
w3 xThe ATP-dependent uptake in 15 s of 10 nM H GS-DNP into
membrane vesicles from GLC4rADR cells was measured with
 .  .no additions 100% , fetal calf serum FCS and serum from
mice, a rat and a guinea pig which had been immunized with the
w xfusion proteins FP-I, FP-III and FP-V 20,21 .
membrane vesicles of GLC4rADR cells was linear
with time for at least 15 s. This uptake was saturable
for GS-DNP and ATP as shown in Fig. 2. The
relation between the uptake rate of GS-DNP and the
ATP or GS-DNP concentration fitted Michaelis-
Menten kinetics. The kinetic constants which were
obtained are summarized in Table 1.
The ATP-dependent uptake of 10 nM of GS-DNP
was studied in the presence and absence of several
polyclonal antibodies raised against MRP as shown
by Fig. 3. Only the polyclonal antiserum raised against
FP-V inhibited the ATP-dependent GS-DNP uptake
to 11"5% compared to a control serum. This may
very well indicate that this segment of MRP is impor-
tant for MRP function.
The influence of several organic compounds on the
ATP-dependent uptake of 10 nM GS-DNP is shown
in Table 2. Organic anions, such as bile acids,
probenecid, GSSG, MTX and calcein inhibited the
GS-DNP transport. Taurine-conjugated bile acids
were potent inhibitors. 3-Sulfated bile acids and more
 .hydrophobic bile acids, such as 3-sulfated taurolito-
cholic acid, were the most potent inhibitors. The
cholephilic organic anion ICG also inhibited GS-DNP
transport. In addition to these organic anions, anthra-
cyclines, vinca alkaloids, VP16, taxol, as well as
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Table 2
Inhibition of the ATP-dependent GS-DNP uptake into GLC4rADR membrane vesicles by several organic compounds
mM percentage of control mM percentage of control
doxorubicin 10 32"4 probenecid 500 55"15
daunorubicin 10 31"1 sulfinpyrazone 500 y1"3
idarubicin 10 52"2 calcein 500 40"3
verapamil 50 97"4 calcein-AM 10 44"10
vincristine 50 46"3 GSSG 100 36"7
vinblastine 50 30"6 ICG 10 34"4
VP-16 10 50"3 TC 10 72"4
taxol 10 66"8 STC 10 76"4
methotrexate 10 82"5 TLC 10 56"5
rhodamine-123 10 104"8 STLC 10 11"2
w3 xUptake in 15 s of 10 nM H GS-DNP into membrane vesicles of GLC4rADR was measured in the presence and absence of 2 mM ATP.
The ATP-dependent uptake of GS-DNP in the presence of the indicated organic compound was related to the ATP-dependent uptake of
GS-DNP in its absence in three separate experiments. Control uptake was 0.76"0.11 pmol GS-DNPrmgrproteinr15 s. The
abbreviations are: ICG, indocyanine green; TC, taurocholate; STC, 3-sulfated TC; TLC, taurolithocholate; STLC, 3-sulfated TLC. Data
 .are presented as mean"S.E.M. nG3 .
calcein-AM inhibited the ATP-dependent transport of
GS-DNP. At the concentrations in which they were
used verapamil and rhodamine-123 did not inhibit
GS-DNP uptake.
w3 xUptake of the organic anions H MTX and
w3 xH GSSG into membrane vesicles prepared from
GLC4rADR cells was also stimulated by ATP Fig.
.4 . This stimulation was absent in membrane vesicles
prepared from GLC4 cells. No significant stimulation
w3 xof the uptake of the anthracycline H DNR by ATP
 .was observed data not shown . The kinetic constants
of GSSG transport are shown in Table 1.
3.2. Inhibition mechanisms
We further studied the nature of the interference of
DNR with GS-DNP uptake representative of the
w xnon-anionic cytostatic drugs 33 . Fig. 5A suggests
that the inhibition by DNR is non-competitive the
slope reflecting the K for GS-DNP is not affectedm
.by DNR . DNR forms complexes with a variety of
w xorganic compounds 34 . The formation of a complex
between GS-DNP and DNR which consequently de-
creases the free GS-DNP concentration could explain
the lowering of GS-DNP transport activity by DNR.
To exclude this possibility we tested whether GS-DNP
could compete with DNA for the binding to DNR. If
binding of DNR to GS-DNP is the cause of inhibi-
tion, the K of such a complex must be in the samed
 .  .range as the K of DNA b.p. and DNR 1–5 mMd
w x35 . GS-DNP alone does not quench the fluorescence
of DNR. DNR is quenched upon binding to DNA but
no decrease was seen in the fluorescence signal of
DNR after the addition of an equal concentration of
 .GS-DNP 1 mM . From this we conclude that seques-
tration of GS-DNP by DNR does not play a role. To
further test this conclusion we studied the dose-de-
pendent inhibition of GS-DNP transport by DNR in
 .the presence of DNA 1 mgrml . DNA buffers the
free DNR concentration. The free DNR concentration
in the presence of 1 mgrml DNA at the same
conditions of the uptake studies was determined as
5% of the total DNR concentration. To obtain the
same inhibitory effect of DNR in the presence of 1
mgrml DNA, we had to apply a 20 times higher
DNR concentration.
We also studied inhibition of GSSG transport by
DNR as shown in Fig. 5B. This figure shows that the
inhibition by DNR of the GSSG transport, in contrast
to that of GS-DNP, was competitive.
The inhibition by DNR of the GS-DNP transport
fitted significantly better to a non-competitive type of
interaction, whereas that of GSSG to a competitive
type of interaction. In order to explain these different
effects we propose a binding pocket that binds in
random order DNR and GS-DNP or GSSG. When
this model was applied to the data of the studies with
GS-DNP transport the best fit with a weighting
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2.factor of 1rY was obtained with a K , f and a ofi
0.95"0.11 mM, 0.32"0.11 and 0.88"0.25 ns
.6 , respectively. With the data of the transport studies
with GSSG we obtained a K , f and a of 0.95"0.32i
 .mM, 0.68"0.72 and 0.09"0.14 ns4 , respec-
tively. The a for GS-DNP and DNR is ;1 which
means non-competitive inhibition. The low a for
Fig. 4. Uptake of GSSG and MTX into membrane vesicles from
w3 x  .GLC4rADR cells. Uptake of 20 nM H GSSG A and 0.3 mM
w3 x  .  .H MTX B into membrane vesicles GLC4 dashed, v, ‘
 .  .and GLC4rADR I, B was measured in the presence v, B
 .or the absence ‘, I of 2 mM ATP as described in Section 2.
Data are from a representative experiment.
Fig. 5. Inhibition by daunorubicin of the ATP-dependent GS-DNP
 .  .A and GSSG uptake B into membrane vesicles from
w3 x  .GLC4rADR cells. The uptake of H GS-DNP A and
w3 x  .H GSSG B was measured at different substrate concentrations
 .at different concentrations of daunorubicin DNR , as indicated.
The data of representative experiments are plotted in a Hofstee
plot. The straight lines are the best fits by the pocket model.
GSSG and DNR shows strongly negatively co-oper-
 .ative competitive binding. Because of this low a , f
could not be predicted accurately. The K of DNRi
found for GS-DNP transport was not significantly
different from that found for GSSG transport. The a
and f for GS-DNP and DNR predict that high con-
centrations of DNR cannot inhibit GS-DNP com-
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Fig. 6. Inhibition by high daunorubicin concentrations of the
ATP-dependent GS-DNP and GSSG uptake into membrane vesi-
w3 xcles from GLC4rADR cells. The uptake of 10 nM H GS-DNP
 . w3 x  .B and H GSSG v was measured at different concentra-
tions of daunorubicin. Uptake without DNR was set at 100%.
pletely. To validate this model we tested this as
shown in Fig. 6. Transport of GSSG was almost
completely inhibited by 500 mM DNR, whereas GS-
DNP transport could not be further inhibited till
;40"20% of the control uptake.
A different explanation may be the presence of
two ATP-dependent transporters for GS-DNP, one
sensitive to DNR and the other insensitive to DNR.
The calculated K of DNR for this proposed DNR-i
sensitive GS-DNP transporter was 0.43"0.13 mM,
which is lower than for the GSSG-transporter.
4. Discussion
This study shows that the GS-conjugate GS-DNP
is transported in an ATP-dependent manner into
membrane vesicles of MRP overexpressing
GLC4rADR cells. This transport was almost absent
from membrane vesicles derived from the drug-sensi-
tive parental cell line, GLC4. Fig. 1 shows that at 10
nM GS-DNP more than 8 pmol of GS-DNP per mg
protein could be taken up in the presence of ATP.
Even if we overestimate the vesicular volume of the
 .plasma membrane vesicles 10 mlrmg prot. and
assume that all these vesicles are inside-out plasma
membranes, there would exist a concentration ratio
for GS-DNP across the membrane which is more
than 80. A significant part of this ratio may corre-
spond to a ratio of free concentrations rather than due
to intravesicular binding, as no such uptake was
observed after long incubation in the absence of ATP.
These results confirm the findings of Muller et al.¨
w x10 . Here, the inhibition by the polyclonal antiserum
raised against a fusion protein containing a segment
of MRP provides additional evidence that the ATP-
dependent transport of GS-DNP and other GS-con-
jugates is mediated by MRP in GLC4rADR cells.
Muller et al. found a higher K of 30 mM for¨ m
GS-DNP transport into vesicles from GLC4rADR
w xcells 10 . It was shown that the ATP-dependent
transport of GS-DNP across plasma membranes of
other cell types had a K ranging from 2 mM to 300m
 w x w x.mM erythrocytes 36–38 and liver 39,40 . These
differences were found when the same cell type was
used, indicating that membrane preparation and ex-
perimental circumstances highly influence the mea-
sured apparent K . The presence of a competitivem
inhibitor could explain an increased apparent K .m
 .Oxidized glutathione GSSG inhibited ATP-de-
pendent GS-DNP transport. GSSG also inhibited
leukotriene-C transport, although to a lower extent;4
w x0.5 mM of GSSG reduced the uptake to 48% 10 .
We found that the uptake of GSSG could be stimu-
lated by ATP in membrane vesicles from
GLC4rADR and not in those from the parent GLC4
cells. The calculated V of GSSG transport 0.9max
.nmolrmgrmin is in the same range as that of
 .GS-DNP 0.56 nmolrmgrmin . This suggests that
GSSG, too, is transported by the system that trans-
ports GS-DNP, i.e., by MRP.
Other organic anions that are not GS-conjugates
could also inhibit the GS-DNP uptake. The substrate
specificity of MRP expressed in GLC4rADR mem-
w xbrane vesicles resembles that of MOAT 28,41 , with
respect to organic anions. The uptake of the in-
hibitory organic anion and anticancer drug MTX, into
GLC4rADR membrane vesicles was stimulated by
ATP. Such a stimulation was not observed for mem-
brane vesicles of GLC4 cells; MTX also appears to
be a substrate of MRP. The ATP-dependent transport
system for MTX described in isolated inside-out
plasma membrane vesicles of L1210 leukemia cells
w x42 may well be MRP proper.
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The fluorescent organic anion calcein has been
w xused as a probe of MRP activity in intact cells 15 .
In the cellular studies the acetoxymethyl ester of
calcein, calcein-AM, was given to cells. This
lipophilic neutral compound diffuses into the cell
where it is hydrolysed to fluorescent calcein. MRP
expressing cells extrude the latter compound. The
interpretation of the studies in intact cells was that
mainly, but not exclusively, the free calcein is ex-
w xtruded by MRP 15 . In this study calcein-AM inhib-
ited transport 30 times more strongly than calcein
itself. As inhibition and transport may be only partly
related, this does not exclude that the actual export
rate of calcein-AM by MRP in intact cells is much
slower than that of calcein.
In addition to calcein-AM many natural product
drugs inhibited GS-DNP transport, although they were
not anionic. The inhibition by vincristine and vinblas-
w xtine confirms the results of Muller et al. 10 . In the¨
quoted publication, these authors could not detect an
inhibition by doxorubicin in their experimental condi-
tions. However, when they applied our membrane
preparation and experimental conditions, both DNR
 .  .10 mM and doxorubicin 10 mM reduced the
 .uptake of leukotriene C 2.3 nM to 47% and 33%,4
 .respectively personal communication by M. Muller .¨
w xThis is in line with the recent work of Loe et al. 43 .
DNR appeared to compete with the binding of
GSSG and inhibited GS-DNP transport in a non-com-
petitive way. The different kinetic behavior of DNR
towards GSSG and GS-DNP transport may suggest
that GSSG and GS-DNP bind to different sites on
MRP. However, it is more likely that both glu-
tathione-conjugates bind to the same site. An alterna-
tive explanation is the presence of two ATP-depen-
dent transporters for GS-DNP, one sensitive to DNR
and the other insensitive to DNR. This is not very
 .likely because 1 both transporters must have the
 .same K for GS-DNP, 2 both transporters must bem
equally induced in GLC4rADR cells and have a low
 .expression in GLC4 cells. 3 The first transporter
must transport GSSG with a K of 43 mM while them
second must be a low affinity system for GSSG,
 .whereas for GS-DNP it is a high affinity system. 4
Many compounds inhibit dose-dependently GS-DNP
transport and can block transport completely data
.  .not shown and 5 the calculated K of DNR for thei
supposed DNR sensitive GS-DNP transporter is half
Fig. 7. Model of the binding pocket of MRP explaining non-com-
petitive inhibition of GS-DNP transport and competitive inhibi-
tion of GSSG transport by DNR.
the K for the GSSG-transporter. However, as expla-i
nation we propose a model including a binding pocket
on MRP in which both DNR and the GS-conjugate
 .bind Fig. 7 . In this model, the pocket is large
enough to bind both GS-DNP and DNR. But if GSSG
is present in the pocket, the binding of DNR is
prevented, possibly by steric hindrance. Accordingly,
when GS-conjugate and DNR are present in the
pocket, GS-conjugate can still be transported. This
may explain the contradictory finding that DNR not
always gives an inhibition of GS-DNP transport.
When the factor f and a equal one DNR will not
give an inhibition of GS-DNP transport.
At the conditions described, uptake of DNR into
membrane vesicles of GLC4rADR cells could not be
stimulated by ATP. This lack of ATP-stimulation
could be caused by a high passive efflux rate of DNR
compared with the active uptake rate, resulting in an
insignificant accumulation. Recently, ATP-dependent
transport of DNR in membrane vesicles from MRP
w xoverexpressing cells has been shown 44 . The analy-
sis of the type of inhibition of GS-DNP and GSSG
transport by DNR suggests that DNR binds to the
same site as, or in the neighborhood of GSSG and
GS-DNP. This makes it plausible that DNR is indeed
 .co- transported by MRP. This model is in agreement
w xwith the results of Loe et al. 43 . They showed that
ATP-dependent accumulation of vincristine in mem-
brane vesicles of MRP expressing cells was stimu-
lated by glutathione.
( )M. Heijn et al.rBiochimica et Biophysica Acta 1326 1997 12–22 21
In this study we showed that MRP transports
organic anions, such as GS-DNP, GSSG and MTX.
This transport is specifically inhibited by a polyclonal
antibody raised against a fusion protein containing a
segment of MRP. At present we are characterizing a
monoclonal antibody that also inhibits ATP-depen-
dent transport of GS-DNP into membrane vesicles
derived from GLC4rADR cells. The kinetics of the
inhibition of anthracyclines suggests the presence of
a binding pocket in MRP. This model of a binding
pocket may be of importance for understanding the
broad substrate specificity of transporters such as
MRP and P-glycoprotein. However, further detailed
kinetic analysis of transport by these proteins is
needed.
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